The document discusses biomedical HIV prevention modalities currently being researched and tested, including microbicides, pre-exposure prophylaxis (PrEP), circumcision, vaccines, and others. It outlines the research processes involved and challenges, and notes that within the next two years results will be seen from several PrEP and microbicide studies that could impact availability and discussions around access and use. Key concerns discussed include understanding and communicating "partial efficacy", monitoring and preventing drug resistance, and ensuring equity in access.

1. Biomedical HIV prevention Bridget Haire

7. HIV Prevention Trial Design (Sharon Hillier, PM2008)‏ Randomisation Active Drug 1 Placebo Active Drug 2 Safe sex counseling Diagnosis & treatment of STIs Condom provision Primary Endpoint HIV seroconversions